LTZ Therapeutics Email Format
Biotechnology ResearchCalifornia, United States11-50 Employees
LTZ Therapeutics is a biotechnology company based in Redwood City, California, focused on immunotherapy research. It is advancing a myeloid engager platform designed to modulate disease processes in cancer and autoimmune disorders, with particular attention to macrophages and other myeloid cell subsets. The work is guided by reverse translational science and emerging disease biology to inform development decisions, with the aim of ultimately addressing cancer. LTZ has announced a strategic collaboration with Eli Lilly to develop myeloid engager therapeutics for diseases with high unmet need, and industry reporting notes a prior collaboration with GlaxoSmithKline in the same area. The company is a smaller biotechnology firm pursuing therapies for both oncology and autoimmune indications. Its base is Redwood City, California, with collaboration activity in Shenzhen, China, reflecting an international development footprint.